We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.00 | 9.00 | 9.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.34 | 52.55M |
From May 2019 to May 2024
TIDMETX
RNS Number : 4297J
e-Therapeutics plc
09 September 2016
e-Therapeutics plc
("e-Therapeutics" or the "Company")
Notification of Half Year Results Date
Oxford and Newcastle, UK - 9 September 2016 - e-Therapeutics plc (AIM: ETX), the drug discovery company, will announce its half year results for the six months ended 31 July 2016 on Tuesday, 20 September 2016.
-Ends-
For more information, please contact:
e-Therapeutics plc Tel: +44 (0)1993 Iain Ross, Chairman 883 125 Steve Medlicott, Finance www.etherapeutics.co.uk Director Numis Securities Limited Tel: +44 (0) 207 Michael Meade / Freddie Barnfield 260 1000 (Corporate Finance) www.numis.com James Black (Corporate Broking) Instinctif Partners Tel: +44 (0) 207 Melanie Toyne Sewell / Jayne 457 2020 Crook / Emma Barlow Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.
The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORVKLBBQKFLBBX
(END) Dow Jones Newswires
September 09, 2016 04:30 ET (08:30 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
